ACADIA Pharmaceuticals Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
ACADIA Pharmaceuticals şirketinin toplam hissedar öz sermayesi $577.2M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $976.9M ve $399.7M dir. ACADIA Pharmaceuticals 'in FAVÖK'ü $112.2M faiz karşılama oranı -4.8 dur. Şirketin $565.3M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.
Anahtar bilgiler
0%
Borç/özkaynak oranı
US$0
Borç
| Faiz karşılama oranı | -4.8x |
| Nakit | US$565.33m |
| Eşitlik | US$577.18m |
| Toplam yükümlülükler | US$399.69m |
| Toplam varlıklar | US$976.87m |
Son finansal sağlık güncellemeleri
We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27
We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Recent updates
Acadia Pharmaceuticals: Proving The Naysayers Wrong
Nov 11ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Nov 08Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
Aug 26The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business
Aug 14ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Aug 01Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
May 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Apr 24We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
Mar 12ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing
Feb 29Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
Jan 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Jan 03We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price
May 22Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah
Oct 19FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide
Sep 12Acadia: Powerful Unfolding Catalysts
Aug 03Acadia Pharma submits marketing application to FDA for trofinetide to treat Rett syndrome
Jul 18Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: ACAD 'nin kısa vadeli varlıkları ( $788.3M ) kısa vadeli yükümlülüklerini ( $343.9M ) aşıyor.
Uzun Vadeli Yükümlülükler: ACAD şirketinin kısa vadeli varlıkları ( $788.3M ) uzun vadeli yükümlülüklerini ( $55.7M ) aşmaktadır.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: ACAD borçsuzdur.
Borcun Azaltılması: ACAD son 5 yıldır borcu bulunmamaktadır.
Borç Kapsamı: ACAD un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.
Faiz Kapsamı: ACAD şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.